HbA\textsubscript{1c} for diagnosis of type 2 diabetes. Is there an optimal cut point to assess high risk of diabetes complications, and how well does the 6.5% cutoff perform?

Abstract: Glycated hemoglobin (HbA\textsubscript{1c}) has recently been recommended for the diagnosis of type 2 diabetes mellitus (T2DM) by leading diabetes organizations and by the World Health Organization. The most important reason to define T2DM is to identify subjects with high risk of diabetes complications who may benefit from treatment. This review addresses two questions: 1) to assess from existing studies whether there is an optimal HbA\textsubscript{1c} threshold to predict diabetes complications and 2) to assess how well the recommended 6.5% cutoff of HbA\textsubscript{1c} predicts diabetes complications. HbA\textsubscript{1c} cutoffs derived from predominantly cross-sectional studies on retinopathy differ widely from 5.2%–7.8%, and among other reasons, this is due to the heterogeneity of statistical methods and differences in the definition of retinopathy. From the few studies on other microvascular complications, HbA\textsubscript{1c} thresholds could not be identified. HbA\textsubscript{1c} cutoffs make less sense for the prediction of cardiovascular events (CVEs) because CVE risks depend on various strong risk factors (eg, hypertension, smoking); subjects with low HbA\textsubscript{1c} levels but high values of CVE risk factors were shown to be at higher CVE risk than subjects with high HbA\textsubscript{1c} levels and low values of CVE risk factors. However, the recommended 6.5% threshold distinguishes well between subjects with and subjects without retinopathy, and this distinction is particularly strong in severe retinopathy. Thus, in existing studies, the prevalence of any retinopathy was 2.5 to 4.5 times as high in persons with HbA\textsubscript{1c}-defined T2DM as in subjects with HbA\textsubscript{1c} <6.5%. To conclude, from existing studies, a consistent optimal HbA\textsubscript{1c} threshold for diabetes complications cannot be derived, and the recommended 6.5% threshold has mainly been brought about by convention rather than by having a consistent empirical basis. Nevertheless, the 6.5% threshold is suitable to detect subjects with prevalent retinopathy, which is the most diabetes specific complication. However, most of the studies on associations between HbA\textsubscript{1c} and microvascular diabetes complications are cross-sectional, and there is a need for longitudinal studies.

Keywords: diabetes mellitus, diagnostic criteria, diagnosis, HbA\textsubscript{1c}, retinopathy

Introduction
Both the American Diabetes Association (ADA) (2012) and an International Expert Committee (IEC) (2009) recommend a glycated hemoglobin (HbA\textsubscript{1c}) level of 6.5% as a cutoff for the diagnosis of type 2 diabetes.\textsuperscript{1,2} Whereas the IEC considers the HbA\textsubscript{1c} as a superior criterion for diagnosis of diabetes, the ADA still sees the HbA\textsubscript{1c} and glucose-based criteria (fasting plasma glucose [FPG] and 2-hour plasma glucose) as equivalent for the diagnosis of diabetes. The World Health Organization (WHO) joined the ADA position and also recommends an HbA\textsubscript{1c} level ≥6.5% as a diagnostic criterion.\textsuperscript{3}
However, in the WHO report, it was stressed that subjects with HbA$_{lc}$ <6.5% can still be diagnosed with diabetes by glucose-based criteria. As for prediabetes, there is still more disagreement: the members of the IEC are in favor of eliminating the category of prediabetes because the risk of diabetes as measured by the HbA$_{lc}$ is continuous. Nevertheless, the IEC recommends that subjects with an HbA$_{lc}$ in the range of 6.0%–6.4% should be given interventions. The ADA recommends using either HbA$_{lc}$ levels (5.7%–6.4%) or the old FPG (100–125 mg/dL) or the oral glucose tolerance test (140–199 mg/dL) criteria to define prediabetes.

There has been an intensive discussion on benefits and drawbacks of the HbA$_{lc}$ for diagnosing diabetes, which has already been summarized in many reviews.$^{4-8}$ An overview of pros and cons of the HbA$_{lc}$ was given by Bonora and Tuomilehto.$^4$ In brief, there are some obvious advantages of the HbA$_{lc}$: there is no need to fast, the HbA$_{lc}$ does not reflect acute events like stress or vigorous physical exercise, the preanalytical stability is larger than in glucose measurements, and coefficients of variation are lower than for FPG and oral glucose tolerance test. An important drawback of the HbA$_{lc}$ as a diagnostic criterion is its dependence on various nonglycemic factors.$^5$ Factors which go together with a decreased turnover of red blood cells, like iron deficiency, renal failure, or vitamin B12 deficiency, lead to higher HbA$_{lc}$ values, whereas factors which coincide with shorter life spans of red blood cells, like hemolytic anemia and chronic liver disease, lead to lower HbA$_{lc}$ levels. Twin studies showed that HbA$_{lc}$ levels also depend on genetic factors.$^6$ Individual characteristics like hemoglobinopathies (hemoglobin [Hb] S, HbC, HbD), age, and ethnicity also have a strong influence on the HbA$_{lc}$. Given an identical glucose level, HbA$_{lc}$ levels were shown to increase by 0.4% for the age range of 40–70 years.$^{9,11}$ Ethnic differences have been found, for example, in Afro-Americans who have considerably higher HbA$_{lc}$ levels than Whites after adjusting for age, sex, FPG, 2-hour plasma glucose, and other metabolic factors.$^{12}$ In a UK multiethnic cohort, South-Asians had a higher HbA$_{lc}$ than White Europeans.$^{13}$

**Focus of the present review**

Although the HbA$_{lc}$ has been adopted for diabetes diagnosis, there are still various open questions related to the HbA$_{lc}$-based diagnosis, which have been recently summarized by Sattar and Preiss.$^{14}$ These authors were right to point out that there is no gold standard for the definition of diabetes, and that therefore, it is not important to what extent different diagnostic criteria diagnose the same subjects with diabetes. However, perhaps the most important open question is, how well does HbA$_{lc}$ predict complications. This was stated as early as 1994 by McCance et al.$^{15}$ “Ultimately such tests can be judged only in terms of their ability to predict a relevant clinical end point, such as the specific complications of diabetes.” An identical statement was made in 2009 by the IEC on the role of the HbA$_{lc}$ in the diagnosis of diabetes:$^2$ “The ultimate goal is to identify individuals at risk for diabetes complications so that they can be treated.”

Therefore, the leading questions of this review are the following:

1. Is there an optimal threshold of the HbA$_{lc}$ to predict complications, including retinopathy and other microvascular and macrovascular complications?
2. How well does the recommended HbA$_{lc}$ threshold of 6.5% fulfill the goal of predicting diabetes complications?
3. In view of the strong dependence of the HbA$_{lc}$ on ethnicity, some authors have brought up the issue of ethnic specific cutoffs. Therefore, the question is, are there ethnic differences in associations of HbA$_{lc}$ levels with diabetes complications?

Sattar and Preiss stated that to judge the ability of diagnostic criteria to predict complications, the focus should be on microvascular complications, not on macrovascular complications.$^{14}$ They argued that newly diagnosed diabetes has now been shown not to be a full equivalent of a former myocardial infarction as previously believed, and that patients with diabetes benefit so strongly from medication, that cardiovascular risk can be brought down below 20%. All the same, macrovascular complications will be taken into account in this review because in persons with diabetes, the burden of disease caused by macrovascular complications is much larger than that of microvascular complications.

**Methods**

To identify literature addressing the associations between HbA$_{lc}$ and microvascular complications, several strategies were used for this narrative review. In the PubMed database, the following terms were combined as medical subject headings or text words: “HbA$_{lc}$” and (threshold or cutoff or cut point) and (microvascular complications or retinopathy or neuropathy or nephropathy or albuminuria). Moreover, an overview published by the WHO in 2010 was used.$^{16}$ Cross-sectional and longitudinal studies were included. For literature identified, we checked the Web of Knowledge citation index for other papers which had cited this literature. Literature on the associations between HbA$_{lc}$ and macrovascular
complications was identified in a similar manner, and two recent meta-analyses were taken into account.

Is there an optimal threshold of the HbA₁c for microvascular complications?

Retinopathy

Ideally, thresholds of HbA₁c for retinopathy are determined in a way that subjects with HbA₁c levels above the threshold have a much larger probability of having or developing retinopathy, and subjects with HbA₁c levels below the threshold have a much lower probability of having or getting this microvascular complication. Table 1 shows characteristics and main findings of studies done to identify thresholds of HbA₁c for retinopathy. Cutoffs range widely from 5.2%–7.8%. In some studies, like the Atherosclerosis Risk In Communities (ARIC) Study, no threshold could be identified. In a further cross-sectional study carried out in Malay people, no threshold was found when change-point models were used for detection of a cutoff. In addition, areas under the receiver operating curve (AROCs) were reported for a few studies. These AROCs can be seen as a measure of how strongly HbA₁c is related to the prevalence or incidence of retinopathy. Most AROCs reported for the association between HbA₁c and prevalent or incident retinopathy are in the range of 0.7–0.8 which can be interpreted as moderate to fairly good. However, in the ARIC and in the Data from an Epidemiological study on the Insulin Resistance syndrome (DESIR) study, lower AROCs were found. The sum of these studies suggests that HbA₁c is associated with prevalent retinopathy, but there is no evidence of a consistent threshold.

Contrary to this conclusion, the recommendations of the IEC to diagnose diabetes by a cutoff of the HbA₁c of 6.5% were based on the assumption that there is a sharp and consistent threshold. In the IEC report, much importance was attached to recent findings of the Evaluation of Screening and Early Detection Strategies for Type 2 Diabetes and Impaired Glucose Tolerance (DETECT-2) study. In DETECT-2, data from nine studies and five countries were pooled, and the number of participants was 44,623. For HbA₁c, a low prevalence of retinopathy was seen until the 17th vigintile, which was followed by a sharp increase. From vigintiles of HbA₁c, a threshold range of 6.3%-6.7% was derived; from continuous levels of HbA₁c, a similar threshold range of 6.5%-6.9% was identified. Finally, a cut point of 6.4% was seen as optimal in receiver operating characteristic curve analysis. It was mainly from these DETECT-2 findings that the IEC recommended a cutoff of 6.5% for the HbA₁c-based diagnosis of diabetes. Moreover, the IEC referred to three epidemiological studies done in the 1990s. This is the study on Pima Indians, on Egyptians, and on US subjects participating in the National Health and Nutrition Examination Survey (NHANES) study. For each of these three studies, prevalence of retinopathy was shown by deciles of HbA₁c, and fairly sharp inflection points were seen by visual inspection.

Ideally, to look for associations between measures of glycemia and long-term complications, longitudinal studies with subjects free of diabetes and free of retinopathy at baseline should be carried out. However, DETECT-2 is a cross-sectional study, and subjects with known diabetes were not excluded, and this applies also to the other three studies mentioned above. Actually, most of the studies presented in Table 1 are cross-sectional studies. So far, there are only three longitudinal studies looking at the association between HbA₁c and retinopathy. However, in the Hoorn study, the number of participants was so low that no threshold was reported. In a recent study on Japanese subjects, follow-up was 3 years, and a threshold range of 6.5%-6.9% was calculated. In the DESIR study, the follow-up was 10 years, and a threshold of 6.0% was derived.

There are several reasons why thresholds of HbA₁c for retinopathy differ so widely in the studies done so far. First, there is a considerable variation in (statistical) methods of determining the cutoffs from HbA₁c data and prevalence or incidence data of retinopathy. As can be seen from Table 1, the most often used methods are visual inspection; calculation of the cutoff, which belongs to the maximum Youden index (the Youden index is the sum of sensitivity and specificity minus 1); change-point models; and logistic regression analyses. Interestingly, thresholds varied strongly even for the same data when different methods were applied. To give an example, in the Australian Diabetes, Obesity and Lifestyle study, the cutoff was 6.1% by visual inspection. When change-point models were used, results strongly depended on model adjustment. Without any adjustment, a threshold of 5.2% was calculated; with adjustment for age, sex, and blood pressure, the threshold was 5.6%, and after a more comprehensive adjustment, the cutoff was 6.0%. In the DETECT-2 study, and the studies on Pima Indians and Egyptians, unadjusted analyses were done.

Second, results depend widely on the definition of retinopathy. In the NHANES study, and the two studies on Pima Indians and Egyptians, strong associations between FPG and retinopathy had been reported with a sharp FPG
Table 1  Studies on the identification of HbA₁c thresholds for prevalent or incident retinopathy

| Study                  | Study population characteristics                               | Definition of retinopathy                                      | Method/criterion of determining cutoff                      | Cutoff | AROC | Sensitivity | Specificity | Cases of retinopathy above/below cutoff |
|------------------------|-----------------------------------------------------------------|----------------------------------------------------------------|-------------------------------------------------------------|--------|------|-------------|------------|----------------------------------------|
| McCance et al¹⁵        | Cross-sectional; 960 Pima Indians; age ≥ 25 years; exclusion of subjects receiving insulin or oral hypoglycemic treatment at the last examination | At least one microaneurysm or hemorrhage or proliferative retinopathy | Crossing point of the two components of a bimodal HbA₁c distribution | 7.8%   | 65.6 | 87.6        | 15.6%      | 1.3%                                   |
|McCance et al¹⁵         | Longitudinal; 960 Pima Indians; age ≥ 25 years; subjects receiving insulin or oral hypoglycemic treatment at baseline were excluded; assessment of incidence of retinopathy after 5 years | At least one microaneurysm or hemorrhage or proliferative retinopathy | Crossing point of the two components of a bimodal HbA₁c distribution | 7.8%⁴  | NR   | 78.1        | 84.7       | Incidence cases above/below cutoff: 22.9%/1.1% |
| Engelgau et al²³       | Cross-sectional; 1,018 Egyptians; age ≥ 20 years; subjects with diabetes not excluded | Bilateral retinal fundus photography | Increase between 7th and 8th decile (entire population) | 6.9%   | 78%  | 78%        | 28%/5%     |                                          |
| Expert committee; NHANES III²⁴ | Cross-sectional; n=2,821; age 40–74 years | Fundus photography | Increase between 9th and 10th decile (excluding subjects with antihyperglycemic medication) | 7.5%   | NR   | NR         | 18%/5.6%   |                                          |
| Itō et al²⁵            | Cross-sectional; 1,208 Japanese exposed to atomic bomb radiation in 1945; age 16–99 years; no exclusion of subjects with known diabetes | Bilateral fundus photography | Test of significant change in prevalence of retinopathy between subsequent decades | 7.3%   | NR   | NR         | 4.2%/1.0%²⁶ |                                          |
| van Leiden et al; Hoorn study²⁵ | Longitudinal; follow-up 7.9–11.0 years; n=233; age 50–74 years; analyses in total study group and in subjects without diabetes | Presence of at least one microaneurysm, hemorrhage, or hard exudate | Logistic model with categories of HbA₁c (adjusted for age, sex, hypertension, glucose metabolism category) | Increase in incidence of retinopathy for HbA₁c in the range of 5.8%–13.1% compared to HbA₁c 4.3%–5.2%; no threshold reported |
| Miyazaki et al; Hisayama study²⁴ | Cross-sectional; 1,637 Japanese; age 40–79 years; no exclusion of subjects with known diabetes | Fundus examination with grading by Airlie House classification | Maximum of Youden index | 5.7%   | 0.945| 86.5        | 90.1       | 20%/2%                                 |

(Continued)
| Study                | Study population characteristics | Definition of retinopathy                                                                 | Method/criterion of determining cutoff                        | Cutoff | AROC   | Sensitivity | Specificity | Cases of retinopathy above/below cutoff |
|---------------------|---------------------------------|----------------------------------------------------------------------------------------|---------------------------------------------------------------|--------|--------|-------------|------------|----------------------------------------|
| Tapp et al; AusDiab study\(^27\) | Cross-sectional; n=2,182; age ≥25 years; no exclusion of subjects with known diabetes | Presence of at least one definite retinal hemorrhage and/or microaneurysm | Visual (total population)                                                                                     | 6.1%   | –      | NR          | NR         | 21.3%/6.6%                             |
|                     |                                 |                                                                                        | Visual (exclusion of subjects on hypoglycemic medication)                                                     | No threshold found | –      | NR          | NR         |                                       |
|                     |                                 |                                                                                        | Change-point model without adjustment                                                                        | 5.2%   | –      | NR          | NR         | NR                      |
|                     |                                 |                                                                                        | Change-point model adjusted for age, sex, blood pressure                                                     | 5.6%   | –      | NR          | NR         | NR                      |
|                     |                                 |                                                                                        | Change-point model with further adjustment for diabetes duration                                              | 6.0%   | –      | NR          | NR         | NR                      |
| Sabanayagam et al\(^20\) | Cross-sectional; 3,190 Malay people; age 40–80 years; subjects with diabetes not excluded | Two digital fundus photographs; retinopathy was defined by ETDRS scores (any ≥15; mild ≥20; moderate ≥43) | Maximization of Youden index for any retinopathy                                                             | 7.0%   | 0.754  | 55.6        | 85.0        | 35.4%/7.2%                             |
|                     |                                 |                                                                                        | Maximization of Youden index for mild retinopathy                                                            | 6.6%   | 0.899  | 87.0        | 77.1        | NR                      |
|                     |                                 |                                                                                        | Maximization of Youden index for moderate retinopathy                                                         | 7.0%   | 0.904  | 82.9        | 82.3        | 15.8%/0.8%                            |
|                     |                                 |                                                                                        | Change-point model for any retinopathy                                                                        | No threshold observed | –      | –          | –          |                                       |
|                     |                                 |                                                                                        | Change-point model for mild retinopathy                                                                       | No threshold observed | –      | –          | –          |                                       |
|                     |                                 |                                                                                        | Change-point model for moderate retinopathy                                                                    | No threshold observed | –      | –          | –          |                                       |
| Cheng et al; NHANES study\(^45\) | Cross-sectional; 1,066 Americans; age ≥40 years | Two 45° nonmydriatic photographs; retinopathy was defined as a score ≥14 by ETDRS severity scale | Joinpoint regression: deciles                                                                                 | 5.5%   | 0.71   | 80          | 37          | 12.7% increase in prevalence of retinopathy above cutoff/0.7% increase below cutoff per 1% increment of HbA\(_1c\) |
|                     |                                 |                                                                                        | Joinpoint regression: Pima cutpoints                                                                        | 5.5%   | –      | –          | –          | 10.5% increase in prevalence of retinopathy above cutoff/0.8% increase below cutoff per 1% increment of HbA\(_1c\) |
| Study | Study population characteristics | Definition of retinopathy | Method/criterion of determining cutoff | Cutoff | AROC | Sensitivity | Specificity | Cases of retinopathy above/below cutoff |
|-------|---------------------------------|---------------------------|---------------------------------------|--------|------|-------------|------------|----------------------------------------|
| Massin et al; DESIR study<sup>21</sup> | Longitudinal; 10 year follow-up; n=700; one group of 235 subjects with diabetes, and two age, sex, and study center matched groups (n=227 and n=238, respectively), with FPG level 110–125 mg/dL, and FPG < 110 mg/dL, respectively; age 30–65 years | Subjects with microaneurysms, hemorrhages, exudates, cotton-wool spots, intravascular abnormalities, venous bleeding, or new vessels | Increase in positive predictive value<sup>c</sup> | 6.0% | 0.64 | 19% | 92% | NR |
| Selvin et al; ARIC study<sup>19</sup> | Cross-sectional; 10,584 subjects without known diabetes | Nonmydriatic 45° retinal photograph; retinopathy was defined by ETDRS scores (none 0, mild 1–4, moderate to severe ≥5) | Cubic-spline models with maximization of likelihood ratio with respect to location of threshold | No evidence for presence of a threshold (AROC for any retinopathy: 0.561 AROC for mild retinopathy: 0.543 AROC for moderate to severe retinopathy: 0.658) |
| Colagiuri et al; DETECT-2 collaboration<sup>22</sup> | Cross-sectional; pooled analysis of nine studies from five countries; n=44,623; age 20–79 years; subjects with known diabetes (13.8%) not excluded | Use of gradable retinal photographs; different methods of classifying and assessing retinopathy between studies | Maximum of Youden index | 6.5%<sup>d</sup> | 80.1<sup>d</sup> | 89.7<sup>d</sup> | -- | -- |
| Xin et al<sup>20</sup> | Cross-sectional; 2,551 Chinese; age 18–79 years; FPG ≥5.6 mmol/L; no exclusion of subjects with known diabetes | Bilateral retinal fundus photography | Maximization of Youden index (total sample) | 6.8% | 0.864 | 85.1 | 88.0 | NR |
| Joinpoint regression (total sample) | 6.9% | 0.725 | 60.7 | 93.6 |
| Joinpoint regression (exclusion of subjects receiving antihyperglycemic medication) | 6.4% | -- | 85.1 | 82.1 | NR |
| Joinpoint regression (exclusion of subjects receiving antihyperglycemic medication) | 6.7% | -- | 60.7 | 91.6 | -- |

<sup>1</sup> Includes microaneurysms, hemorrhages, exudates, cotton-wool spots, intravascular abnormalities, venous bleeding, or new vessels. 
<sup>2</sup> Includes microaneurysms, hemorrhages, exudates, cotton-wool spots, intravascular abnormalities, venous bleeding, or new vessels. 
<sup>3</sup> Includes microaneurysms, hemorrhages, exudates, cotton-wool spots, intravascular abnormalities, venous bleeding, or new vessels. 
<sup>4</sup> Includes microaneurysms, hemorrhages, exudates, cotton-wool spots, intravascular abnormalities, venous bleeding, or new vessels.
Table 1 (Continued)

| Study                  | Study population characteristics                                                                 | Definition of retinopathy                                                                 | Method/criterion of determining cutoff                                                                 | Cutoff | AROC  | Sensitivity | Specificity | Cases of retinopathy above/below cutoff |
|------------------------|-------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------|--------|-------|-------------|-------------|-----------------------------------------|
| Tsugawa et al<sup>26</sup> | Cross-sectional; 20,433 Japanese subjects; age ≥21 years; subjects with known diabetes not excluded | Presence of hard exudates, cotton wool spots, retinal hemorrhage, or more severe forms of retinopathy; Fukuda standard A2 or higher | Test for nonlinearity in multivariate logistic regression models with restricted cubic spline              |        |       |             |             | No threshold found for prevalence of retinopathy (test for nonlinearity: P=0.08) |
| Tsugawa et al<sup>26</sup> | Longitudinal; 3 years follow-up; 19,987 Japanese subjects; age ≥21 years; subjects with known diabetes not excluded | Presence of hard exudates, cotton wool spots, retinal hemorrhage, or more severe forms of retinopathy; Fukuda standard A2 or higher | Test for nonlinearity in multivariate logistic regression models with restricted cubic spline              |        |       |             |             | “Possible threshold at HbA₁c levels between 6.0 and 7.0” (test for nonlinearity: P=0.001) |
| Cho et al<sup>29</sup> | Cross-sectional; 3,403 participants from South Korea; age 40–69 years; 24% of the subjects had diabetes by ADA criteria | Single-field nonmydriatic fundus photography                                             | Maximization of Youden index: any retinopathy                                                          | 6.6%   | 0.83  | 76.2        | 84.2        | 8.4%/0.5%                              |
|                        |                                                                                                 |                                                                                         | Maximization of Youden index: moderate/severe retinopathy                                              | 6.9%   | 0.84  | 77.1        | 88.7        | 6.6%/0.3%                              |
|                        |                                                                                                 |                                                                                         | Logistic regression (unadjusted): any retinopathy                                                       | 6.9%   | -     | 68.3        | 89.0        | 10.5%/0.7%                             |
|                        |                                                                                                 |                                                                                         | Logistic regression (unadjusted): moderate/severe retinopathy                                        | 6.9%   | -     | 77.1        | 88.7        | 6.6%/0.3%                              |
|                        |                                                                                                 |                                                                                         | Logistic regression (multivariable adjustment): any retinopathy                                       | 6.9%   | -     | 68.3        | 89.0        | 10.5%/0.7%                             |
|                        |                                                                                                 |                                                                                         | Logistic regression (multivariable adjustment): moderate/severe retinopathy                           | 6.9%   | -     | 77.1        | 88.7        | 6.6%/0.3%                              |

Notes: ¹The value “9.4%” indicated in Table 2 of the paper by McCance et al (1994) is obviously a mistake. ²Prevalence of retinopathy below threshold was calculated by the authors. ³Visual inspection of the frequency of retinopathy according to baseline HbA₁c would lead to a much larger cutoff but was not assessed by the authors. ⁴Values were calculated for the middle of the range. ⁵Abbreviations: 2hPG, 2-hour plasma glucose; ADA, American Diabetes Association; ARIC, Atherosclerosis Risk in Communities; AROC, area under the receiver operating characteristic curve; AusDiab, Australian Diabetes Obesity and Lifestyle study; DEsIR, Data from an Epidemiological Study on the Insulin Resistance Syndrome; DETECT-2, Evaluation of Screening and Early Detection Strategies for Type 2 Diabetes and Impaired Glucose Tolerance; ETDRS, Early Treatment Diabetic Retinopathy Study; FPG, fasting plasma glucose; HbA₁c, glycated hemoglobin; NHANeS, National Health and Nutrition Examination Survey; NR, not reported.
cutoff of 7.0 mmol/L. However, as pointed out by Wong et al, a direct clinical ophthalmoscopic examination was done in the Pima Indian study, and only one retinal photograph was taken in the two other studies. When multiple retinal photographs of each eye were used to diagnose retinopathy, the association between FPG and retinopathy was much weaker as indicated by AROCs between 0.56–0.61, and no sharp threshold could be observed anymore.

Accordingly, thresholds of HbA1c for retinopathy may also depend on the method used to diagnose retinopathy. Furthermore, mild retinopathy can also occur in persons without diabetes, and thresholds for mild retinopathy can differ from thresholds for moderate retinopathy. In a South Korean study, for example, the cutoff derived from AROCs was 6.6% for any retinopathy, and 6.9% for moderate or severe retinopathy. In Malay people, thresholds of 6.6% and 7.0%, respectively, were calculated from receiver operating characteristic curves for mild and moderate retinopathy. The methods sections of some papers suggest that studies differ in the definition of what is a mild or moderate retinopathy. To give an example, in the ARIC study and in the Malay study, grades of retinopathy were defined according to a modification of the so-called Arlie House classification system, which had been used in the Early Treatment Diabetic Retinopathy study (ETDRS). In ARIC, mild retinopathy was defined as ETDRS 14–20, where as ETDRS ≥20 (and ≤43) was used as a criterion for mild retinopathy in the Malay study.

Third, thresholds of HbA1c for retinopathy depend on the choice of exclusion criteria. In a Chinese study, for example, a cutoff of 6.4% was determined for the whole study group when a nonlinear regression model was used. After exclusion of subjects receiving antihyperglycemic medication, the cutoff was 6.7% with use of the same method.

Fourth, HbA1c distributions may not be the same for different ethnicities, and a shift of HbA1c distributions to the left or to the right would influence the position of the threshold. The question of ethnicity-specific cutoffs will be discussed in more detail below.

Fifth, thresholds were identified from deciles of HbA1c in many studies. Thus, the choice of cutoffs depends strongly on the position of deciles, and thus on the distribution of HbA1c. Particularly in smaller study groups, the precise position of deciles may to some extent depend on chance.

Sixth, discrepancies in threshold assessment might be due to differences in the measurement of HbA1c, in particular in older studies which were carried out when the standardization of HbA1c measurements was less advanced.

Other microvascular complications

Meanwhile, there are a lot of studies on thresholds for retinopathy, but as can be seen from Table 2, there are fewer studies on thresholds for other microvascular complications.

As indicated by AROCs, associations between HbA1c and prevalent/incident microvascular complications other than retinopathy are quite poor. So far, AROCs have been reported in the ARIC study and in the Malay study, and range from 0.56–0.67. Moreover, in most studies, no thresholds were reported. In the Malay study, cutoffs of HbA1c for chronic kidney disease (6.6%), microalbuminuria or macroalbuminuria (7.0%) and peripheral neuropathy (6.6%) were obtained from maximizing the Youden index. However, maximizing the Youden index and reporting the corresponding cutoff is always possible. The sums of sensitivity and specificity calculated for these cutoffs in the Malay study are in the range of 1.1–1.2, which is again quite poor – remember that a figure of 1 for the sum of sensitivity and specificity corresponds to the minimum of information possible. For the cutoffs calculated for retinopathy, the sums of sensitivity and specificity were in the range of 1.5–1.6 in most studies, and thus demonstrated that cutoffs of HbA1c were much sharper in retinopathy than in other microvascular complications. When change-point modeling was used in the Malay study, no thresholds of HbA1c for microvascular complications other than retinopathy could be found anymore. In the Australian Diabetes, Obesity and Lifestyle study, a cutoff of HbA1c was found for microalbuminuria by visual inspection. However, change-point modeling gave no evidence for a threshold anymore.

The studies shown in Table 2 are all cross-sectional, and subjects with known diabetes were not excluded. The only exception is the ARIC study, which is longitudinal with a long follow-up and an analysis stratified for participants with and without diabetes. In this study, it became particularly evident that there is no threshold of HbA1c for chronic kidney disease and end-stage renal disease, respectively.

Macrovascular complications

In several meta-analyses, associations between glycemic measures and cardiovascular diseases have been found in ranges of glycemia usually seen as nondiabetic. To give an example, an HbA1c level of 5% is far below the cut points recommended for the diagnosis of prediabetes or diabetes. Nevertheless, as shown in more detail below, the risk of CVE has been shown to be larger for subjects with an HbA1c level of 5% compared to subjects with an HbA1c level of 4.27%. This is not surprising because increased cardiovascular risk
### Table 2: Studies on the identification of HbA\textsubscript{1c} thresholds for prevalence or incidence of microvascular complications (except retinopathy)

| Study                        | Study characteristics                                                                 | Microvascular complication | Method of determining cutoff | Cutoff | Sensitivity | Specificity | Cases above/below cutoff | AROC  |
|-----------------------------|----------------------------------------------------------------------------------------|-----------------------------|-------------------------------|--------|-------------|-------------|--------------------------|-------|
| McCance et al\textsuperscript{15} | Cross-sectional; 960 Pima Indians; age ≥25 years; exclusion of subjects receiving insulin or oral hypoglycemic treatment at the last examination | Nephropathy                 | Crossing point of the two components of a bimodal HbA\textsubscript{1c} distribution | 7.8%   | 40.0        | 86.6        | 7.5%/1.8%                | –     |
|                             | Longitudinal; 960 Pima Indians; age ≥25 years; subjects receiving insulin or oral hypoglycemic treatment at baseline were excluded; assessment of incidence of retinopathy after 5 years | Nephropathy                 | Crossing point of the two components of a bimodal HbA\textsubscript{1c} distribution | 7.8%\textsuperscript{a} | –           | –           | 3.8%/1.4%                | –     |
| Tapp et al; AusDiab\textsuperscript{27} | Cross-sectional; n=2,389; age ≥25 years; no exclusion of subjects with known diabetes | Microalbuminuria             | Visual inspection              | 6.1%   | NR          | NR          | 29.8%/11.2%              | –     |
| Sabanayagam et al\textsuperscript{30} | Cross-sectional; 3,190 Malay people; age 40–80 years; subjects with diabetes not excluded | Chronic kidney disease       | Maximum of Youden index       | 6.6%   | 37.9        | 76.6        | –                        | 0.615 |
|                             | Microalbuminuria or macroalbuminuria                                                  | Maximum of Youden index     | 7.0%                          | 31.8   | 90.6        | –                        | 0.673 |
|                             | Peripheral neuropathy                                                                  | Maximum of Youden index     | 6.6%                          | 66.5   | 41.5        | –                        | 0.573 |
|                             | Chronic kidney disease or macroalbuminuria                                            | Change-point model           | No threshold observed         | –      | –           | –                        | –     |
|                             | Chronic kidney disease or macroalbuminuria                                            | Change-point model           | No threshold observed         | –      | –           | –                        | –     |
|                             | Microalbuminuria or macroalbuminuria                                                  | Change-point model           | No threshold observed         | –      | –           | –                        | –     |
|                             | Peripheral neuropathy                                                                  | Change-point model           | No threshold observed         | –      | –           | –                        | –     |
|                             | Chronic kidney disease or macroalbuminuria                                            | Maximum likelihood ratio method | No evidence for a threshold (P-values for presence of a threshold: P=0.54 (adjustment for age, sex, and race; P=0.59 [multivariable adjustment]) | –      | –           | –                        | 0.562 |
| Selvin et al; ARIC study\textsuperscript{19} | Longitudinal; median of follow-up 14 years; 10,584 subjects without diabetes at baseline | Chronic kidney disease       | Maximum likelihood ratio method | 5.5%   | 82          | 55          | –                        | 0.76  |
| Bongaerts et al; KORA F4 study\textsuperscript{46} | Cross-sectional; n=1,100; age 61–82 years; no exclusion of subjects with known diabetes | Distal sensorimotor polyneuropathy (DSPN) | Logistic regression with categories of HbA\textsubscript{1c} | 5.5%   | 82          | 55          | –                        | –     |
| Hernandez et al\textsuperscript{47} | Cross-sectional; n=2,270; age 18–80 years; no exclusion of subjects with known diabetes | Combined endpoint of chronic kidney disease or cardiovascular disease | Maximum of Youden index     | 5.5%   | 82          | 55          | –                        | –     |

**Note:** The figure "9.4%" indicated in Table 2 of the paper by McCance (1994) is obviously a mistake.

**Abbreviations:** HbA\textsubscript{1c}, glycated hemoglobin; ARIC, Atherosclerosis Risk in Communities; AROC, area under the receiver operating characteristic curve; AusDiab, Australian Diabetes Obesity and Lifestyle study; KORA, Cooperative Health Research in the Region of Augsburg; NR, not reported.
has not been used as a criterion for the selection of cutoffs of glycemic measures.

In two older reviews, continuous relationships were reported between glucose levels and CVE which started in the nondiabetic range and continued in the diabetic range.\(^{32,33}\) Although the studies presented in these reviews were based on measurements of fasting glucose, 1- and 2-hour glucose, and random glucose, the conclusions drawn in these reviews might be relevant for the question of relationships between glycemic measures (including HbA\(_{1c}\)) and CVE in general. Coutinho et al stated that it is difficult to tell from an exponential curve whether it is continuous or whether there is a threshold, and moreover, that a threshold might be even below the prediabetic range if there were a threshold at all.\(^{32}\)

A more recent meta-analysis covered seven prospective studies which included nine datasets with cardiovascular disease (CVD) as the outcome, and seven datasets with cardiovascular death as the outcome.\(^{17}\) As a result, the risk of CVE was increased even in slightly higher HbA\(_{1c}\) levels. With an HbA\(_{1c}\) level of 4.27% as a reference, the risk of CVE was 13% higher for an HbA\(_{1c}\) level of 5%, 34% higher for an HbA\(_{1c}\) level of 6%, and 58% higher for an HbA\(_{1c}\) level of 7%. From the meta-analysis, an exponential relationship was derived between HbA\(_{1c}\) and cardiovascular death which did not suggest the existence of a threshold. In a further recent meta-analysis of nine prospective studies on the association of HbA\(_{1c}\) with coronary heart disease (CHD), a significant overall association in the nondiabetic range was found (hazard ratio [HR] = 1.20, 95% confidence interval [CI] 1.10-1.31); however, a threshold was not reported in this meta-analysis.\(^{18}\)

Results from the ARIC study on the relationship between HbA\(_{1c}\) and cardiovascular risk in 11,092 Black and White US adults, with a median follow-up of 14 years, were not included in the two meta-analyses.\(^{34}\) After multivariable adjustment, a clear trend was found between categories of HbA\(_{1c}\) and CHD (P<0.001) and HbA\(_{1c}\) and ischemic stroke (P<0.001). With HbA\(_{1c}\) 5.0 to <5.5% as the reference, the CHD risk increased by 23% for HbA\(_{1c}\) 5.5 to <6.0%, by 78% for 6.0 to <6.5%, and by 95% for HbA\(_{1c}\) \(\geq 6.5\). The authors assumed that there was “a possible threshold” of HbA\(_{1c}\) for CHD risk: for HbA\(_{1c}\) <5.0% as the reference, a HR of 1.38 (95% CI 1.22–1.56) per 1% of HbA\(_{1c}\) was reported for HbA\(_{1c}\) levels above 5.5%.

To conclude, there is strong evidence of a continuous association between HbA\(_{1c}\) and CVD. Some authors discuss a threshold of HbA\(_{1c}\) for CVD far below the diabetic threshold, but there is little evidence that this could be a sharp cutoff.

**How well does the recommended HbA\(_{1c}\) threshold of 6.5% fulfill the goal of predicting diabetes complications?**

As shown above, no distinct and consistent threshold of HbA\(_{1c}\) was found for retinopathy. For other microvascular complications and for macrovascular complications no convincing evidence has been presented for the existence of a threshold.

In view of the many methodical problems which come up upon selecting a threshold, even for retinopathy, we would suggest a more pragmatic decision. The recommended HbA\(_{1c}\) threshold of 6.5% is acceptable if the frequency of prevalent/incident complications is considerably higher in subjects with HbA\(_{1c}\)-defined diabetes than in subjects with a lower HbA\(_{1c}\).

In several cross-sectional studies, the prevalence of any retinopathy was considerably higher for HbA\(_{1c}\) \(\geq 6.5\)% than for HbA\(_{1c}\) <6.5% (Tables 3 and 4). In the Reykjavik study, the Malay study, and the NHANES study (Whites), respectively, prevalence of any retinopathy was 2.5, 4.5, and 3.0 times as high in persons with HbA\(_{1c}\)-defined diabetes as in subjects with HbA\(_{1c}\) levels below the threshold.\(^{20,35,36}\) In the ARIC study, however, subjects with HbA\(_{1c}\) \(\geq 6.5\)% did not have larger odds of any retinopathy (HR = 0.91, 95% CI 0.54–1.54) than subjects with HbA\(_{1c}\) <5.7% after multivariable adjustment.\(^{19}\) When these analyses were confined to more severe grades of retinopathy, the 6.5% threshold distinguishes much better between subjects with and without prevalent retinopathy. In the Reykjavik study, the prevalence of moderate retinopathy was 2.5% for HbA\(_{1c}\) \(\geq 6.5\)% but only 0.1% for lower HbA\(_{1c}\) levels.\(^{35}\) In the Malay study, the prevalence of moderate retinopathy was about 30 times higher in HbA\(_{1c}\) levels than in HbA\(_{1c}\) <6.5%.\(^{20}\) In the ARIC study, the odds of moderate/severe retinopathy was 2.9 (95% CI 1.2–7.1) times higher in HbA\(_{1c}\) \(\geq 6.5\)% than in HbA\(_{1c}\) <6.5%.\(^{19}\)

However, the 6.5% threshold distinguishes less well between persons with and without microvascular complications other than retinopathy. In the Malay study, for example, the prevalence of chronic kidney disease was 29.9% in subjects with HbA\(_{1c}\) \(\geq 6.5\)% and 17.8% in subjects with lower HbA\(_{1c}\) levels.\(^{20}\) For prevalence of microalbuminuria and macroalbuminuria, the corresponding figures were 58.9% and 29.6%, respectively; and for prevalence of
peripheral neuropathy, these figures were 23.9% and 16.7%, respectively.

For cardiovascular outcomes, establishing an HbA₁c threshold makes less sense than for microvascular complications because CVD risk depends on many strong risk factors, including HbA₁c itself. This was demonstrated in the European Prospective Investigation of Cancer Norfolk study for 10,144 men and women free of diabetes at baseline. With adjustment for age only, the relative risk of CVD was 1.31 (95% CI 1.13–1.52) in HbA₁c 5.5%–5.9%, 1.50 (95% CI 1.22–1.84) in HbA₁c 6.0%–6.4%, 2.19 (95% CI 1.55–3.09) in HbA₁c 6.5%–6.9%, and 3.21 (95% CI 2.50–4.13) in HbA₁c ≥7.0% (reference HbA₁c <5.5%). However, participants with a lower level of HbA₁c, but raised values of other CVD risk factors (eg, systolic blood pressure, ratio of total cholesterol to HDL cholesterol, smoking) had a much higher risk of CVD than participants with a high HbA₁c level and lower values of the other CVD risk factors.

Studies on CVD prediction models confirm that glycemic measures are of minor importance for the assessment of CVD risk. In the Framingham Offspring study, the AROC of the sex-adjusted Framingham Risk score for the prediction of CVD was 0.744. When HbA₁c was added to this prediction model, the AROC was 0.740, ie, there was no improvement of CVD prediction at all. This finding confirms that prediction of macrovascular complications should only play a marginal role with regard to HbA₁c thresholds for diabetes. The idea that the HbA₁c should be combined with other risk factors in preventive interventions was demonstrated in the Anglo-Danish-Dutch study of Intensive Treatment in People with Screen Detected Diabetes in Primary Care (ADDITION) study. Subjects who might benefit from interventions were defined by either screen detected diabetes or by excess mortality. HbA₁c alone identified only 20% of those who might benefit from lifestyle intervention or medical treatment, whereas a combination of HbA₁c ≥6.0% and an elevated cardiovascular risk, defined by the Systematic Coronary Risk Evaluation (SCORE) of ≥5, identified 96.7% of these subjects.

In the Danish part of the ADDITION study, it was demonstrated that the 6.5% threshold of HbA₁c is useful to predict mortality in subjects with normal glucose tolerance. After multivariable adjustment, the risk of all-cause mortality was significantly increased for HbA₁c ≥6.5% (HR =2.48, 95% CI 1.23–4.99) compared to HbA₁c <6.0%. Thus, in this Danish study group, normal glucose tolerance subjects with HbA₁c ≥6.5% had a similar risk of all-cause mortality as subjects with known type 2 diabetes. However, a limitation

### Table 3 Association of HbA₁c based diagnosis of type 2 diabetes (HbA₁c ≥6.5%) with prevalence or incidence of microvascular complications

| Study | Study characteristics | Microvascular complication considered | Prevalence of microvascular complications |
|-------|------------------------|----------------------------------------|------------------------------------------|
| Sabanaygam et al²⁹ | Cross-sectional study in Malay people; age 40–80 years; subjects with diabetes not excluded; n=3,190 (chronic kidney disease) n=930 (microalbuminuria and macroalbuminuria) n=855 (peripheral neuropathy) | Prevalence of any retinopathy | HbA₁c ≥6.5% 28.6% HbA₁c <6.5% 6.4% |
| | | Prevalence of mild retinopathy | 17.2% 0.8% |
| | | Prevalence of moderate retinopathy | 12.2% 0.4% |
| | | Prevalence of chronic kidney disease | 29.9% 17.8% |
| | | Prevalence of microalbuminuria and macroalbuminuria | 58.9% 29.6% |
| | | Prevalence of peripheral neuropathy | 23.9% 16.7% |
| Tsugawa et al³⁶ | Cross-sectional; 2,527 White and 805 Black Americans; age ≥40 years | Prevalence of retinopathy (subjects not treated for T2DM, Whites only) | HbA₁c ≥6.5% 12.3% (95% CI 4.5–20.1) HbA₁c <6.5% 4.1%³ |
| | | Prevalence of retinopathy (subjects not treated for T2DM, Blacks only) | 17.1% (95% CI 6.9–27.2) 6.7%³ |
| Gunnslaugsdottir; Reykjavik study (AGES-R)³⁵ | Cross-sectional; n=4,994; age ≥67 years | Prevalence of any retinopathy (subjects not treated for T2DM, Blacks only) | HbA₁c ≥6.5% 27.0% (95% CI 23.2–31.0) |
| | | Prevalence of mild retinopathy | 23.4% (95% CI 19.8–27.4) 10.7% (95% CI 9.8–11.6) |
| | | Prevalence of moderate retinopathy | 2.5% (95% CI 1.4–4.3) 10.6% (95% CI 9.7–11.5) |
| | | Prevalence of proliferative diabetic retinopathy | 1.0% (95% CI 0.3–2.3) 0.1% (95% CI 0.0–0.2) |

**Note:** Prevalence of retinopathy below threshold was calculated by the authors.

**Abbreviations:** HbA₁c, glycated hemoglobin; AGES-R, the Age, Gene/Environment Susceptibility – Reykjavik Study; CI, confidence interval; T2DM, type 2 diabetes mellitus.
of this analysis was the quite low number of subjects with HbA₁c ≥6.5%.

Should there be ethnicity-specific thresholds of the HbA₁c for the diagnosis of diabetes?

As mentioned in the introduction, HbA₁c levels vary considerably with ethnicity. In particular, Blacks have higher HbA₁c levels than Whites at any glycemic level, and therefore, higher thresholds for Blacks have been discussed. The question whether there are ethnic differences in the association between HbA₁c and prevalent retinopathy was examined in two recent cross-sectional studies.³⁶,⁴¹

In nondiabetic participants of the NHANES study, the mean HbA₁c level was lowest in non-Hispanic Whites (5.5%), and highest in non-Hispanic Blacks (5.7%); for Hispanic Americans, it was 5.6%.³¹ When subjects with HbA₁c ≥6.5% were compared to subjects with HbA₁c <5.7%, the age–sex adjusted odds ratios (ORs) for retinopathy were 1.22 (95% CI 0.47–3.16), 2.71 (95% CI 1.06–6.93), and 3.32 (95% CI 1.61–6.86), respectively, in non-Hispanic Whites, non-Hispanic Blacks, and Hispanic Americans. Although the two latter ORs were much larger than the OR for non-Hispanic Whites, the interaction term between ethnicity and a level of HbA₁c was not statistically significantly related to the prevalence of retinopathy (P=0.72), and this was also found after further multivariable adjustment. Therefore, the authors see no support for ethnic-specific HbA₁c thresholds.

In another analysis of NHANES data, a significant increase in the risk of diabetic retinopathy was seen at lower levels of HbA₁c in Blacks than in Whites; the risk of retinopathy started to increase in Blacks with HbA₁c 5.5%–5.9% and in Whites with HbA₁c 6.0%–6.4%.³⁵ From this, the authors drew the conclusion that the HbA₁c threshold to diagnose...
diabetes should not be increased in Blacks. From the results of this study alone, one might even draw the conclusion that the threshold of the HbA\textsubscript{ic} should even be lower for Blacks than Whites. We assume that the authors did not go that far given the strong evidence that HbA\textsubscript{ic} levels are generally higher in Blacks than in Whites.

**Conclusion**

Identification of HbA\textsubscript{ic} thresholds for the diagnosis of diabetes is mainly based on studies of the association between HbA\textsubscript{ic} levels and retinopathy because retinopathy is the most diabetes-specific complication. For other microvascular complications, associations with HbA\textsubscript{ic} are too weak, as far as this can be seen from the very few available cross-sectional studies. For macrovascular complications, HbA\textsubscript{ic} is only one among various other strong risk factors. Thus, identification of thresholds mainly relies on one single microvascular complication which covers only a small part of the burden of type 2 diabetes mellitus complications.

The existing studies on the association between HbA\textsubscript{ic} and retinopathy have important drawbacks. Most studies are cross-sectional, subjects with known diabetes have often not been excluded, confounders (like age, sex, blood pressure) are often not adjusted for. Cutoffs suggested by these studies vary widely from 5.2%–7.8%, and thresholds depend strongly on statistical methods, on definition of retinopathy, and the distribution of HbA\textsubscript{ic} in the study group. Even for a given data set, cutoffs differ widely with regard to the statistical method. The whole of the studies suggests that the recommended 6.5% threshold has mainly been brought about by convention rather than having a consistent empirical basis.

By now, we recommend a somewhat pragmatic access, which is to examine how well the 6.5% criterion does at distinguishing subjects with retinopathy from subjects without retinopathy. The few studies which allow an answer to this question indicate that the prevalence of any retinopathy is 2.5 to 4.5 times higher in subjects with HbA\textsubscript{ic} $\geq$6.5% than in subjects with lower HbA\textsubscript{ic} levels. For severe retinopathy, these factors are even much higher. In some cross-sectional studies, prevalence of any retinopathy was quite high, even for HbA\textsubscript{ic} <6.5%, ie, 10.7% in the Reykjavik study and 6.4% in the Malay study.\textsuperscript{20,25} However, any retinopathy may also have nondiabetic reasons, and moreover, these studies were done in older study groups.

There is still another reason why the HbA\textsubscript{ic} threshold should be dealt with in a pragmatic way. Many doctors do not follow guidelines and do not strictly follow the criteria for the diagnosis of diabetes. In a study in US veterans done before the recommendation of the new HbA\textsubscript{ic} criteria, it was shown that only 2% of doctors met the criteria of diagnosing diabetes recommended at that time.\textsuperscript{42} Nevertheless, 4 years later, 88% of the patients who had received a diagnosis of diabetes actually had HbA\textsubscript{ic} $\geq$6.5% or received diabetes medication. Obviously, the predictive accuracy is much larger than the diagnostic accuracy. Thus, in the real world, criteria for the diagnosis of diabetes do not have to be perfect but in some way reasonable to work within clinical practice. In this regard, the 6.5% threshold seems to be a sensitive, pragmatic solution. However, there is a strong need for longitudinal studies on the associations between HbA\textsubscript{ic} and microvascular complications with subjects free of diabetes and diabetes complications at baseline. Only if such studies gave a strong indication for other HbA\textsubscript{ic} thresholds should the discussion on the best HbA\textsubscript{ic} cutoff be reopened.

**Disclosure**

The authors declare no conflicts of interest in this work.

**References**

1. American Diabetes Association. Executive summary: Standards of medical care in diabetes – 2012. *Diabetes Care*. 2012;35(Suppl 1):S4–S10.
2. International Expert Committee. International Expert Committee report on the role of the A\textsubscript{ic} assay in the diagnosis of diabetes. *Diabetes Care*. 2009;32(7):1327–1334.
3. Use of glycated haemoglobin (HbA\textsubscript{ic}) in the diagnosis of diabetes mellitus. Abbreviated report of a WHO consultation [webpage on the Internet]. Geneva: World Health Organization; 2011. Available from: http://www.who.int/diabetes/publications/diagnosis_diabetes2011/en/. Accessed October 1, 2013.
4. Bonora E, Tuomilehto J. The pros and cons of diagnosing diabetes with A\textsubscript{ic}. *Diabetes Care*. 2011;34 Suppl 2:S184–S190.
5. Dankner R, Bergman M, Danoff A, et al. The metabolic deterioration that antedates diabetes: personal trajectories of HbA\textsubscript{ic} and fasting glucose as early indicators and possible triggers for intervention. *Diabetes Metab Res Rev*. 2013;29(1):1–7.
6. Hare MJ, Shaw JE, Zimmet PZ. Current controversies in the use of haemoglobin A\textsubscript{ic} as early indicators and possible triggers for intervention. *Diabetes Metab Res Rev*. 2013;29(1):1–7.
7. John WG; UK Department of Health Advisory Committee on Diabetes. Use of HbA\textsubscript{ic} in the diagnosis of diabetes mellitus in the UK. The implementation of World Health Organization guidance 2011. *Diabet Med*. 2012;29(11):1350–1357.
8. Malkani S, Mordes JP. Implications of using hemoglobin A\textsubscript{ic} for diagnosing diabetes mellitus. *Amer J Med*. 2011;124(5):395–401.
9. Snieder H, Sawtell PA, Ross L, Walker I, Spector TD, Leslie RD. HbA\textsubscript{ic} levels are genetically determined even in type 1 diabetes: evidence from healthy and diabetic twins. *Diabetes*. 2001;50(12):2858–2863.
10. Pani LN, Korenda L, Meigs JB, et al. Effect of aging on A\textsubscript{ic} levels in individuals without diabetes: evidence from the Framingham Offspring Study and the National Health and Nutrition Examination Survey 2001–2004. *Diabetes Care*. 2008;31(10):1991–1996.
11. Davidson MB, Schriger DL. Effect of age and race/ethnicity on HbA\textsubscript{ic} levels in people without known diabetes mellitus: implications for the diagnosis of diabetes. *Diabetes Res Clin Pract*. 2010;87(3):415–421.
12. Herman WH, Ma Y, Uwaifo G et al; Diabetes Prevention Program Research Group. Differences in A\textsubscript{ic} by race and ethnicity among patients with impaired glucose tolerance in the Diabetes Prevention Program. *Diabetes Care*. 2007;30(10):2453–2457.
13. Mostafa SA, Khunti K, Srinivasan BT, Webb D, Gray LJ, Davies MJ. The potential impact and optimal cut-points of using glycated haemoglobin, HbA1c, to detect people with impaired glucose regulation in a UK multi-ethnic cohort. *Diabetes Res Clin Pract*. 2010;90(1):100–108.

14. Sattar N, Preiss D. HbA1c in type 2 diabetes diagnostic criteria: addressing the right questions to move the field forwards. *Diabetologia*. 2012;55(6):1564–1567.

15. McCance DR, Hanson RL, Charles MA et al. Comparison of tests for glycated haemoglobin and fasting and two hour plasma glucose concentrations as diagnostic methods for diabetes. *BMJ*. 1994;308(6940):1323–1328.

16. World Health Organization. *HbA1c in the Diagnosis of Type 2 Diabetes: a Systematic Review*. Geneva: World Health Organization. Available from: http://www.who.int/diabetes/publications/syst_rev_hba1c_web.pdf. Accessed July 24, 2013.

17. Santos-Oliveira R, Purdy C, da Silva MP, dos Anjos Carneiro-Leão AM, Machado M, Einaron TR. Haemoglobin A1c levels and subsequent cardiovascular disease in persons without diabetes: a meta-analysis of prospective cohorts. *Diabetología*. 2011;54(6):1327–1334.

18. Sarwar N, Aspelund T, Eiriksdottir G, et al. Markers of dysglycaemia and risk of coronary heart disease in people without diabetes: Reykjavik prospective study and systematic review. *PLoS Med*. 2010;7(5):e1000278.

19. Selvin E, Ning Y, Steffes MW, et al. Glycated hemoglobin and the risk of kidney disease and retinopathy in adults with and without diabetes. *Diabetes*. 2011;60(1):298–305.

20. Sabanayagam C, Liew G, Tai ES et al. Relationship between glycated haemoglobin and microvascular complications: is there a natural cut-off point for the diagnosis of diabetes? *Diabetologia*. 2009;52(7):1279–1289.

21. Massin P, Lange C, Tichet J, et al; DESIR (Data From an Epidemiological Study on the Insulin Resistance Syndrome) Study Group. Haemoglobin A1c and fasting plasma glucose levels as predictors of retinopathy at 10 years: the French DESIR study. *Arch Ophthalmol*. 2011;129(2):188–195.

22. Colaguri S, Lee CMY, Wong TY, Balkau B, Shaw JE, Borch-Johnsen K; DETECT-2 Collaboration Writing Group. Glycemic thresholds for diabetes-specific retinopathy: implications for diagnostic criteria for diabetes. *Diabetes Care*. 2011;34(1):145–150.

23. Engelgau MM, Thompson TJ, Herman WH, et al. Comparison of fasting and 2-hour glucose and HbA1c levels for diagnosing diabetes. Diagnostic criteria and performance revisited. *Diabetes Care*. 1997;20(5):785–791.

24. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. *Diabetes Care*. 1997;20(7):1183–1197.

25. van Leiden HA, Dekker JM, Moll AC et al. Risk factors for incident retinopathy in a diabetic and nondiabetic population: the Hoorn study. *Arch Ophthalmol*. 2003;121(2):245–251.

26. Tsugawa Y, Takahashi O, Meigs JB, et al. New diabetes diagnostic threshold of hemoglobin A1c and the 3-year incidence of retinopathy. *Diabetes*. 2012;61(12):3280–3284.

27. Tapp RJ, Zimmer PZ, Harper CA et al; AusDiab Study Group. Diagnostic thresholds for diabetes: the association of retinopathy and albuminuria with glycemia. *Diabetes Res Clin Pract*. 2006;73(3):315–321.

28. Wong TY, Liew G, Tapp RJ, et al. Relation between fasting glucose and retinopathy for diagnosis of diabetes: three population-based cross-sectional studies. *Lancet*. 2008;371(9614):736–743.

29. Cho NH, Kim TH, Woo SJ, et al. Optimal HbA1c cutoff for detecting diabetic retinopathy. *Acta Diabetol*. Epub January 25, 2013.

30. Xin Z, Yuan MX, LiHX, et al. Evaluation for fasting and 2-hour glucose and HbA1c for diagnosing diabetes based on prevalence of retinopathy in a Chinese population. *PLoS One*. 2012;7(7):e40610.

31. Sarwar N, Gao P, Seshasai SR, et al; Emerging Risk Factors Collaboration. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. *Lancet*. 2010;375(9733):2215–2222.
Optimal HbA1c cut point for the diagnosis of type 2 diabetes